INVESTIGATION ALERT (NYSE: PACS): DiCello Levitt LLP Is Investigating Investor Claims Against PACS Group, Inc. and Encourages PACS Investors with Losses to Contact the Firm

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dicello Levitt LLP announces that it has launched an investigation into whether PACS Group, Inc. (“PACS” or the “Company”) (NYSE: PACS) complied with federal securities laws. The Firm’s investigation focuses on whether the Company violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors.

Investors who purchase PACS securities and those with information about the allegations are encouraged to obtain additional information and assist the Firm’s investigation by contacting DiCello Levitt attorneys Brian O’Mara or Hani Farah by calling (888) 287-9005 or emailing investors@dicellolevitt.com. Those who inquire by email are encouraged to include their mailing address, telephone number, and the number of shares purchased.

No Case Has Been Filed and No Class Has Been Certified. Until a case is filed and a class is certified, you are not represented by counsel unless you retain one.   You may select counsel of your choice.

Investigation Details:

PACS is a Utah-based operator of skilled nursing facilities (“SNFs”), which typically serve patients “who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after they have been discharged from the hospital” but “still require 24-hour in-patient services.” Since 2019, PACS has grown its SNFs portfolio by 240% by adding over 145 locations. Since April 11, 2024, when PACS issued its initial public offering (“IPO”), its stock price has risen ~104%, making it one of the most successful IPOs of 2024.

On November 4, 2024, Hindenburg Research published a critical research report titled “PACS Group: How To Become A Billionaire In The Skilled Nursing Industry By Systematically Scamming Taxpayers,” alleging, among other things, that it “revealed that PACS’ ‘turnaround’ strategy largely boils down to systematically scamming taxpayer-funded healthcare programs.”   According to the report, Hindenburg Research claims that the alleged fraud, abuse of a COVID-era waiver that enabled inappropriate access to skilled care Medicare benefits, and improper billing and staffing schemes is confirmed as a result of a five-month investigation, through interviews with former employees and competitors, and an analysis of 900+ detailed facility-level cost reports.

In response to the Hindenburg Research report, shares of PACS plummeted approximately 27% to close at $31.01 per share on November 4, 2024.

About DiCello Levitt

At DiCello Levitt, we are dedicated to achieving justice for our clients through class action, business-to-business, public client, whistleblower, personal injury, civil and human rights, and mass tort litigation. Our lawyers are highly respected for their ability to litigate and win cases – whether by trial, settlement, or otherwise – for people who have suffered harm, global corporations that have sustained significant economic losses, and public clients seeking to protect their citizens’ rights and interests. Every day, we put our reputations – and our capital – on the line for our clients.

DiCello Levitt has achieved top recognition as Plaintiffs Firm of the Year and Trial Innovation Firm of the Year by the National Law Journal, in addition to its top-tier Chambers and Benchmark ratings. The New York Law Journal also recently recognized DiCello Levitt as a Distinguished Leader in trial innovation. For more information about the Firm, including recent trial victories and case resolutions, please visit www.dicellolevitt.com.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Media Contact

Amy Coker
4747 Executive Drive, Suite 240
San Diego, CA 92121
619-963-2426
investors@dicellolevitt.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.